GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicus Pharma Ltd (TSXV:MDCX) » Definitions » Capex-to-Revenue

Medicus Pharma (TSXV:MDCX) Capex-to-Revenue : 0.00 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Medicus Pharma Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Medicus Pharma's Capital Expenditure for the three months ended in Sep. 2024 was C$0.00 Mil. Its Revenue for the three months ended in Sep. 2024 was C$0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Medicus Pharma Capex-to-Revenue Historical Data

The historical data trend for Medicus Pharma's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicus Pharma Capex-to-Revenue Chart

Medicus Pharma Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Revenue
- - -

Medicus Pharma Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Medicus Pharma's Capex-to-Revenue

For the Drug Manufacturers - General subindustry, Medicus Pharma's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicus Pharma's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicus Pharma's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Medicus Pharma's Capex-to-Revenue falls into.



Medicus Pharma Capex-to-Revenue Calculation

Medicus Pharma's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

Medicus Pharma's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicus Pharma  (TSXV:MDCX) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Medicus Pharma Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Medicus Pharma's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicus Pharma Business Description

Traded in Other Exchanges
Address
100 King Street West, Suite 3400, One First Canadian Place, Toronto, ON, CAN, M5X 1A4
Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.